Grace Therapeutics (GRCE) Long-Term Investments (2018 - 2019)
Grace Therapeutics (GRCE) posted Long-Term Investments of $20302.4 for Q1 2019, down 1.31% sequentially from $20571.3 in Q1 2018, and down 1.31% YoY from $20571.3 in Q1 2018.
Grace Therapeutics (GRCE) Long-Term Investments (2018 - 2019) Analysis & Trends
Grace Therapeutics has reported Long-Term Investments for 2 years, with the latest figure at $20302.4 in Q1 2019.
- Quarterly Long-Term Investments fell 1.31% year-over-year to $20302.4 in Q1 2019, while the trailing twelve-month figure through Mar 2019 was $20302.4 (down 1.31% YoY) and the FY2019 annual result came in at $20000.0, down 2.78% from the prior year.
- Long-Term Investments retreated to $20302.4 in Q1 2019 per GRCE's latest filing, from $20571.3 in the prior quarter.
- Over five years, Long-Term Investments peaked at $20571.3 in Q1 2018 and troughed at $20302.4 in Q1 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1.77 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 22.17 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 372.10 Mn |
| 10 | Grace Therapeutics | 37.99 Mn | 37.99 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2019 | 20,302.36 |
| Mar 31, 2018 | 20,571.31 |